Eylea (aflibercept intravitreal) / Bayer, Regeneron, Chong Kun Dang - LARVOL DELTA

GOBI: Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03) (clinicaltrials.gov) - P3 | N=450 | Not yet recruiting | Sponsor: Ollin Biosciences, Inc.

New P3 trial • Diabetic Macular Edema • Ophthalmology

ATACAMA: Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02) (clinicaltrials.gov) - P3 | N=450 | Not yet recruiting | Sponsor: Ollin Biosciences, Inc.

New P3 trial • Diabetic Macular Edema • Ophthalmology

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (clinicaltrials.gov) - P3 | N=534 | Recruiting | Sponsor: Adverum Biotechnologies, Inc. | N=284 ➔ 534

Enrollment change • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A method to quantify ligand-neuron binding in vivo. (PubMed, J Neurosci Methods) - "The unique organization of the RGC layer enables a robust, non-disruptive in vivo ligand-neuron binding assay that preserves native cell-surface receptors. This platform is compatible with ligandomics and can be applied to map disease-selective neuronal ligands, providing a foundation for developing targeted neuroprotective therapies for retinal disorders."

Journal • Preclinical • Ophthalmology • Retinal Disorders

Recurrent Anterior Uveitis Associated with Teclistamab in Relapsed/Refractory Multiple Myeloma (IMS 2026) - " The patient had previously received multiple treatment lines, including VTd, lenalidomide-dexamethasone, daratumumab-based therapy, and KPd, which was discontinued after ocular thrombotic complications... We describe a rare case of recurrent anterior uveitis temporally associated with teclistamab exposure in RRMM. The recurrence after rechallenge and exclusion of infectious or viral etiologies support a possible immune-mediated mechanism. This report highlights the importance of multidisciplinary management and close ophthalmologic monitoring in patients receiving BCMA-directed bispecific antibodies."

Glaucoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Uveitis

Impact of faricimab and high-dose aflibercept on treatment demand in a tertiary ophthalmic centre in Norway. (PubMed, Acta Ophthalmol) - "The introduction of faricimab and high-dose aflibercept was associated with reduced per-patient treatment intensity, while the treated population continued to increase. Longer-acting anti-VEGF drugs may reduce pressure on retinal services by lowering injection frequency; however, their introduction was associated with higher overall costs."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Rapid choroidal neovascularization after non-flap internal limiting membrane peeling for macular hole in a patient with AMD: a case report and literature review. (PubMed, BMC Ophthalmol) - "This case suggests that, in eyes with underlying AMD, CNV may develop rapidly after standard ILM peeling even without an ILM flap technique. Biomechanical stress related to ILM removal, potentially involving macular displacement and mechanical stress on Müller cells, may be a possible contributing factor, but causality cannot be established from a single case. Physicians should maintain high vigilance for this vision-threatening complication during the early postoperative period after MH surgery."

Journal • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Incidence and Clinical Course of Intraocular Inflammation Following Pharmacy-Compounded Intravitreal Aflibercept 8mg for Neovascular AMD: A Real-World Cohort Study. (PubMed, Clin Ophthalmol) - "To evaluate the incidence and clinical course of intraocular inflammation (IOI) after intravitreal aflibercept 8 mg (Eylea 8 mg - E8) injection in patients with neovascular age-related macular degeneration (nAMD) in Poland...All cases were managed with topical corticosteroids, 16/20 additionally received sub-Tenon triamcinolone, and 6 required oral prednisolone; 1 patient required pars plana vitrectomy...In this first Polish cohort study, the incidence of IOI after E8 injection (2.31% per eye/patient) was higher than reported in registration trials, though episodes were generally mild and self-limited, without long-term visual impact. These findings may help inform clinical monitoring for patients receiving E8 for nAMD."

Journal • Real-world evidence • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis • Wet Age-related Macular Degeneration

Clustered sterile intraocular inflammation following intravitreal aflibercept injections: involvement of 2 mg, 8 mg, and biosimilar formulations. (PubMed, Eye (Lond)) - No abstract available

Journal • Inflammation • Ocular Inflammation

A Prospective, Multicenter, Open-Label Phase IV Clinical Study to Evaluate the Biomarkers, Effectiveness, and Safety Based On A Modified Fixed Dose Regimen of Aflibercept 8mg in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration (nAMD) (ChiCTR) - P2 | N=49 | Not yet recruiting | Sponsor: Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital

Biomarker • New P2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • CXCL8 • VEGFB

Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: Tanta University | Not yet recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Jul 2026 | Trial primary completion date: Nov 2025 ➔ Jun 2026

Trial completion • Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology • Retinal Vein Occlusion

Patient-Reported Quality of Life and Treatment Experiences Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept in Colombia: A Qualitative Study. (PubMed, Clin Ophthalmol) - "Although treatment generated fear and discomfort at the beginning, it also represented an opportunity to maintain autonomy and social participation. These findings highlight the importance of patient-centered care strategies that integrate psychosocial support, clear communication, and continuous access to treatment."

HEOR • Journal • Age-related Macular Degeneration • Macular Degeneration • Mood Disorders • Ophthalmology • Psychiatry • Retinal Disorders • Wet Age-related Macular Degeneration

Two-dose aflibercept 8 mg versus three-dose aflibercept 2 mg loading for treatment-naïve neovascular age-related macular degeneration. (PubMed, PLoS One) - "This shortened loading phase potentially reduces the initial treatment burden. Further prospective studies should validate these preliminary outcomes."

Journal • Retrospective data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

MOJAVE: Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04) (clinicaltrials.gov) - P3 | N=500 | Not yet recruiting | Sponsor: Ollin Biosciences, Inc.

New P3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (clinicaltrials.gov) - P3 | N=240 | Active, not recruiting | Sponsor: EyePoint Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetic Macular Edema • Ophthalmology

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (clinicaltrials.gov) - P3 | N=240 | Active, not recruiting | Sponsor: EyePoint Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetic Macular Edema • Ophthalmology

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) (clinicaltrials.gov) - P3 | N=960 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

Re: Holz et al.: Adherence to intravitreal aflibercept in neovascular age-related macular degeneration: 24-month results from the ANDROMEDA Study (Ophthalmol. Retina. 2026;10:241-249). (PubMed, Ophthalmol Retina) - No abstract available

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

ASCEND: A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P2 | N=244 | Not yet recruiting | Sponsor: Everest Medicines (China) Co.,Ltd.

New P2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration (clinicaltrials.gov) - P=N/A | N=54 | Completed | Sponsor: Saglik Bilimleri Universitesi | Recruiting ➔ Completed

Real-world evidence • Trial completion • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Bilateral choroidal thinning during unilateral aflibercept for neovascular age-related macular degeneration: 5-year mixed-effects analysis. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "In this 5-year three-group longitudinal analysis, treated eyes showed the greatest annual reduction in CCT, fellow untreated eyes showed an intermediate reduction, and age-matched control eyes showed the smallest decline. The inclusion of a control group indicated that fellow-eye thinning exceeded that expected from physiological aging alone, supporting bilateral choroidal change during long-term unilateral IVA therapy."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Artificial Intelligence-Assisted Analysis of Retinal Pigment Epithelium Tears in Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept (2 mg and 8 mg) and Faricimab: A Single-Centre Retrospective Case Series. (PubMed, J Clin Med) - " RPE tears were an uncommon, predominantly early complication occurring in eyes with large PEDs, with no excess risk from second-generation agents. AI-assisted OCT may aid anatomical characterisation, and most eyes retained vision with continued therapy."

Journal • Retrospective data • Age-related Macular Degeneration • Hematological Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Pachychoroid diseases of the macula: an update. (PubMed, Med Hypothesis Discov Innov Ophthalmol) - "Pachychoroid spectrum disorders share common choroidal vascular and hemodynamic abnormalities despite considerable phenotypic variability. Ongoing advances in multimodal imaging and evolving therapeutic strategies continue to refine the understanding and management of these disorders."

Journal • Review • Age-related Macular Degeneration • Developmental Disorders • Ophthalmology • Retinal Disorders

Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: West China Hospital

New P2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO (clinicaltrials.gov) - P3 | N=910 | Recruiting | Sponsor: Kodiak Sciences Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetic Macular Edema • Ophthalmology